论文部分内容阅读
以平均年龄63(28～80)岁的59(男48、女11)例慢性重度心力衰竭(左室喷血分数 <35％)病人为对象;其中缺血性心脏病38例、原发性扩张型心肌病18例和主动脉瓣返流3例;双侧肾动脉狭窄病人和内生肌酐清除率(CCr) <10ml/min的重度肾功能不全病人已经除外。试验前停用血管扩张剂至少5天。试验前和试验期间,控制钠摄入量(2g/d),洋地黄和利尿剂用量保持不变。试验期间(血管紧张素)转换酶抑制剂用量不变:39例口服卡托普利,平均剂量为218(75～450)mg/d;其余20例口服enalapril,平均剂量为38(20～40)mg/d。测值以均值±标准误表示。
Fifty-nine patients (48 males and 11 females) with chronic heart failure (LV ejection fraction <35%) aged 63 to 28 years old were enrolled in this study. Among them, 38 were ischemic heart disease, Dilated cardiomyopathy in 18 cases and aortic valve regurgitation in 3 cases; patients with bilateral renal artery stenosis and endogenous creatinine clearance rate (CCr) <10ml / min patients with severe renal insufficiency have been excluded. Disrupt vasodilators for at least 5 days before testing. Control sodium intake (2g / d) before and during the trial, digitalis and diuretic dosage remained unchanged. During the experiment, the amount of ACE inhibitor was unchanged: 39 patients received captopril, with an average dose of 218 (75-450) mg / d; the remaining 20 patients enalapril, with an average dose of 38 (20-40 ) mg / d. Measured values are expressed as mean ± standard error.